Mehmet Oz, head of the US Centers for Medicare & Medicaid Services (CMS), said the Trump administration is seeking additional voluntary drug-pricing agreements with pharmaceutical companies. Officials have announced more than 20 such deals so far, Oz said, and more are in the works. The agreements vary, but companies typically agree to lower prices charged to public health programs and to launch new drugs at prices comparable with other developed countries in exchange for tariff relief.

Juneyao Health said at an earnings briefing it is optimizing core SKUs and refining its product mix based on consumer insights. In 1H 2026 the company worked with more than 1,800 influencers (KOL/KOC), generating over 96 mln brand exposures. Online e-commerce revenue in 1H reached 177 mln yuan, up 91.9% YoY, with e-commerce becoming a major incremental channel driving consumer probiotic market penetration.

At its 2026 interim results online briefing, Heshun Petroleum said its refined-oil retail and wholesale business is entering a period of structural adjustment and upgrading. The company has acquired Kuixin Technology as a strategic entry into the semiconductor sector and said it will continue to increase investment in semiconductors to diversify and hedge cyclicality in its traditional oil business, citing rapid downstream demand growth and a domestic-substitution window.